Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Rev. am. med. respir ; 22(2): 247-252, jun. 2022. graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1441137

RESUMO

ABSTRACT Patients infected with SARS-CoV2 show various manifestations consistent with the multiorgan impact of this virus in the system of the human being. However, pulmonary conditions are the most predominant: from slight ground glass infiltrates to severe involvement of pulmonary parenchyma. Pneumomediastinum is a rare expression that only occurs in 1% of patients. We present the case of a critically ill male patient with COVID-19 who develops pneumomediastinum without pneumothorax.


RESUMEN Los pacientes infectados por SARS-CoV2 presentan manifestaciones variadas consecuentes con el impacto multiorgánico de este virus en la economía del ser humano. Sin embargo, las afecciones pulmonares son las predominantes, dado que abarcan desde sutiles infiltrados en "vidrio esmerilado" hasta un gran compromiso del parénquima pulmonar. El neumomediastino es una expresión rara que se presenta tan solo en un 1% de los pacientes. Presentamos el caso de un paciente varón con COVID-19 crítico que desarrolla neumomediastino sin neumotórax.

2.
Rev. am. med. respir ; 22(2): 165-169, jun. 2022. ilus
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1441122

RESUMO

Los pacientes infectados por SARS-CoV2 presentan manifestaciones variadas consecuentes con el impacto multiorgánico de este virus en la economía del ser humano. Sin embargo, las afecciones pulmonares son las predominantes, dado que abarcan desde sutiles infiltrados en "vidrio esmerilado" hasta un gran compromiso del parén quima pulmonar. El neumomediastino es una expresión rara que se presenta tan solo en un 1% de los pacientes. Presentamos el caso de un paciente varón con COVID-19 crítico que desarrolla neumomediastino sin neumotórax.


Patients infected with SARS-CoV2 show various manifestations consistent with the multiorgan impact of this virus in the system of the human being. However, pulmonary conditions are the most predominant: from slight ground glass infiltrates to severe in volvement of pulmonary parenchyma. Pneumomediastinum is a rare expression that only occurs in 1% of patients. We present the case of a critically ill male patient with COVID-19 who develops pneumomediastinum without pneumothorax.


Assuntos
Enfisema Mediastínico
3.
Curr Top Med Chem ; 21(11): 964-975, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34061003

RESUMO

The peroxisome proliferator activated receptors (PPARs) are a superfamily of well-recognized ligand-binding nuclear receptors comprising three isoforms: PPARα, PPARγ, and PPARß/δ. In response to endogenous lipid messengers, PPARs trigger the transcription of genes related to a wider spectrum of physiological phenomena, including fatty acid oxidation, inflammation, adipogenesis, among many others. Thus, the importance of PPARs as putative protective therapy in health issues has increased the interest of studying these nuclear receptors, including the management of neurodegenerative disorders, multiple sclerosis, and likely addiction. In recent years, several pieces of evidence from animal models have demonstrated the promising role of PPARs as a critical element for interventions in addictive behaviors by reducing the reinforcing properties of addictive substances such as alcohol. However, there is a lack of data in the scope and has so far been unexplored the function of PPARs in additional drugs such as cannabis, opioids, methamphetamine, or cocaine. A similar scenario has been found for the management of binge-type eating disorders. Thus, here we review recent advances in understanding the relevance of the PPAR controlling addiction.


Assuntos
Comportamento Aditivo/tratamento farmacológico , Terapia de Alvo Molecular/métodos , Receptores Ativados por Proliferador de Peroxissomo/metabolismo , Preparações Farmacêuticas/metabolismo , Álcoois/metabolismo , Analgésicos Opioides/metabolismo , Analgésicos Opioides/farmacologia , Cannabis/metabolismo , Cocaína/metabolismo , Cocaína/farmacologia , Humanos , Ligantes , Metanfetamina/metabolismo , Metanfetamina/farmacologia , Doenças Neurodegenerativas/tratamento farmacológico , Nicotina/metabolismo , Oxirredução , Isoformas de Proteínas , Receptores Citoplasmáticos e Nucleares/metabolismo , Fatores de Transcrição/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA